TY - JOUR
T1 - Case report
T2 - Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy
AU - Torrado, Carlos
AU - Baysal, Mehmet A.
AU - Chakraborty, Abhijit
AU - Norris, Becky L.
AU - Khawaja, Fareed
AU - Tsimberidou, Apostolia M.
N1 - Publisher Copyright:
Copyright © 2024 Torrado, Baysal, Chakraborty, Norris, Khawaja and Tsimberidou.
PY - 2024
Y1 - 2024
N2 - A patient in his 40s with splenic angiosarcoma metastatic to the liver underwent splenectomy, chemotherapy, and partial hepatectomy before being treated on a clinical trial with CTLA4 and PD1 inhibitors. He had received pneumococcal and meningococcal vaccines post-splenectomy. On week 10, he developed grade 3 immune-related colitis, successfully treated with the anti-tumor necrosis factor-alpha inhibitor infliximab and steroids. After 4 cycles of treatment, scans showed partial response. He resumed anti-PD1 therapy, and 6 hours after the second dose of anti-PD1 he presented to the emergency room with hematemesis, hematochezia, hypotension, fever, and oxygen desaturation. Laboratory tests demonstrated acute renal failure and septicemia (Streptococcus pneumoniae). He died 12 hours after the anti-PD1 infusion from overwhelming post-splenectomy infection (OPSI). Autopsy demonstrated non-viable liver tumors among other findings. In conclusion, patients undergoing immunotherapy and with prior history of asplenia should be monitored closely for OPSI as they may be at increased risk.
AB - A patient in his 40s with splenic angiosarcoma metastatic to the liver underwent splenectomy, chemotherapy, and partial hepatectomy before being treated on a clinical trial with CTLA4 and PD1 inhibitors. He had received pneumococcal and meningococcal vaccines post-splenectomy. On week 10, he developed grade 3 immune-related colitis, successfully treated with the anti-tumor necrosis factor-alpha inhibitor infliximab and steroids. After 4 cycles of treatment, scans showed partial response. He resumed anti-PD1 therapy, and 6 hours after the second dose of anti-PD1 he presented to the emergency room with hematemesis, hematochezia, hypotension, fever, and oxygen desaturation. Laboratory tests demonstrated acute renal failure and septicemia (Streptococcus pneumoniae). He died 12 hours after the anti-PD1 infusion from overwhelming post-splenectomy infection (OPSI). Autopsy demonstrated non-viable liver tumors among other findings. In conclusion, patients undergoing immunotherapy and with prior history of asplenia should be monitored closely for OPSI as they may be at increased risk.
KW - CTLA4
KW - immuno-therapy
KW - immunology
KW - infection
KW - OPSI
KW - splenectomy
UR - http://www.scopus.com/inward/record.url?scp=85193717414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85193717414&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2024.1366271
DO - 10.3389/fimmu.2024.1366271
M3 - Article
C2 - 38779675
AN - SCOPUS:85193717414
SN - 1664-3224
VL - 15
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1366271
ER -